UA106209C2 - Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid - Google Patents

Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid

Info

Publication number
UA106209C2
UA106209C2 UAA201103353A UAA201103353A UA106209C2 UA 106209 C2 UA106209 C2 UA 106209C2 UA A201103353 A UAA201103353 A UA A201103353A UA A201103353 A UAA201103353 A UA A201103353A UA 106209 C2 UA106209 C2 UA 106209C2
Authority
UA
Ukraine
Prior art keywords
choline cocrystal
phenylpropenylidene
thioxo
oxo
methyl
Prior art date
Application number
UAA201103353A
Other languages
English (en)
Ukrainian (uk)
Inventor
Изабель Калофонос
Г. Патрик Стехли
Вильям Мартин-Дойл
Димитрис Калофонос
Джефри С. Сталтс
Тревис Л. Хьюстон
Original Assignee
Бионевия Фармасьютикалз, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бионевия Фармасьютикалз, Инк filed Critical Бионевия Фармасьютикалз, Инк
Publication of UA106209C2 publication Critical patent/UA106209C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение касается нового водородного двухкислотного сокристалла холина 5-[(1Z,2Е)- 3-фенилпропенилиден]- 3-тиазолидинуксусной кислоты.В документе представлена информация по получению и описание нового сокристалла холина согласно разным вариантам изобретения.Изобретение касается фармацевтических соединений, содержащих новый сокристалл холина, и связанно с терапевтическим применением нового сокристалла холина для лечения и профилактики разных заболеваний, включая лечение и профилактику осложнений диабета, лечение и профилактику гомоцистинурии, связанной с уменьшением уровней гомоцистеина в сыворотке крови, ингибирование альдозоредуктазы, а также создание кардиопротекторного эффекта у пациентов без диабета.
UAA201103353A 2008-09-06 2009-09-03 Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid UA106209C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9490408P 2008-09-06 2008-09-06
PCT/US2009/055868 WO2010028132A2 (en) 2008-09-06 2009-09-03 Novel choline cocrystal of epalrestat

Publications (1)

Publication Number Publication Date
UA106209C2 true UA106209C2 (en) 2014-08-11

Family

ID=41797847

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201103353A UA106209C2 (en) 2008-09-06 2009-09-03 Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid

Country Status (17)

Country Link
US (3) US8906948B2 (ru)
EP (1) EP2326632B8 (ru)
CN (1) CN102216281B (ru)
AU (1) AU2009288037B2 (ru)
CA (1) CA2738231C (ru)
CY (1) CY1119752T1 (ru)
DK (1) DK2326632T3 (ru)
EA (2) EA016904B1 (ru)
ES (1) ES2639019T3 (ru)
GB (1) GB2476202B (ru)
HU (1) HUE034456T2 (ru)
LT (1) LT2326632T (ru)
PL (1) PL2326632T3 (ru)
PT (1) PT2326632T (ru)
SI (1) SI2326632T1 (ru)
UA (1) UA106209C2 (ru)
WO (1) WO2010028132A2 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
DK2326632T3 (en) 2008-09-06 2017-09-18 Bionevia Pharmaceuticals Inc New choline crystal of epalrestate
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
RU2017124629A (ru) * 2011-01-20 2019-01-30 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
ITMI20120586A1 (it) 2012-04-11 2013-10-12 Milano Politecnico Co-cristalli di 3-iodiopropinil butilcarbammato
CN103951634B (zh) * 2014-05-07 2016-06-08 浙江东亚药业股份有限公司 一种依帕司他结晶盐水合物和羟基哌啶共晶物及其制备方法和应用
AU2015267312B2 (en) * 2014-05-27 2018-06-28 Artificial Cell Technologies, Inc. Automated layer by layer construction of multilayer coated cores by TFF
WO2020205846A1 (en) 2019-04-01 2020-10-08 Applied Therapeutics Inc. Inhibitors of aldose reductase
EP3966320A4 (en) * 2019-05-07 2023-10-25 University of Miami TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS
CN113336718B (zh) * 2021-06-01 2023-02-28 天津大学 依帕司他-二甲双胍盐及其制备方法和应用
CN113354596B (zh) * 2021-06-01 2022-11-29 天津大学 依帕司他-二甲双胍盐丙酮溶剂化物及制备方法和应用
CN113292511B (zh) * 2021-06-01 2022-11-25 天津大学 依帕司他-二甲双胍盐乙醇水双溶剂化物及制备方法和应用
CN113277962B (zh) * 2021-06-01 2023-02-07 天津大学 依帕司他-二甲双胍盐水合物及其制备方法和应用
CN115947699B (zh) * 2023-01-16 2024-01-19 威海海洋职业学院 以烟酰胺为前驱体的依帕司他共晶及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1247067A (en) 1968-02-16 1971-09-22 Fujisawa Pharmaceutical Co Tricyclic enol ether compounds and the preparation thereof
JPS5740478A (en) 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
JPS5852220A (ja) 1981-09-24 1983-03-28 Fujisawa Pharmaceut Co Ltd 血清尿酸値低下剤
JPS6251955A (ja) 1985-08-22 1987-03-06 Sansei Seiyaku Kk 飼料組成物
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
GB9526264D0 (en) 1995-12-21 1996-02-21 Knoll Ag Medical treatment
WO1997035584A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
EP1106210A3 (en) 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
JP2004514700A (ja) * 2000-11-30 2004-05-20 ファイザー・プロダクツ・インク Ｇａｂａアゴニスト及びアルドース還元酵素阻害剤の組み合わせ
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP3547010B1 (ja) * 2002-12-27 2004-07-28 小野薬品工業株式会社 ５−［（１ｚ，２ｅ）−２−メチル−３−フェニル−２−プロペニリデン］−４−オキソ−２−チオキソ−３−チアゾリジン酢酸の結晶の製造方法およびその製剤
CA2514092C (en) 2003-01-21 2013-03-19 S.S.C.I., Inc. Novel cocrystallization of hydrochloric acid salt of an active agent
WO2005055983A2 (en) * 2003-12-09 2005-06-23 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
JP2005298424A (ja) * 2004-04-13 2005-10-27 Sawai Pharmaceutical Co Ltd エパルレスタット結晶の製造方法
JP4892821B2 (ja) 2004-09-30 2012-03-07 大日本印刷株式会社 エパルレスタット製造法
JP4892915B2 (ja) * 2005-10-04 2012-03-07 大日本印刷株式会社 エパルレスタット製造法
US20110275695A1 (en) 2008-06-13 2011-11-10 Bionevia Pharmaceuticals, Inc. Crystalline forms of zotepine hydrochloride
EA018905B1 (ru) 2008-07-25 2013-11-29 Бионевия Фармасьютикалс, Инк. Новый бетаиновый сокристалл эпалрестата
WO2010011922A2 (en) 2008-07-25 2010-01-28 Bionevia Pharmaceuticals, Inc. Novel crystalline salts of epalrestat
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
DK2326632T3 (en) 2008-09-06 2017-09-18 Bionevia Pharmaceuticals Inc New choline crystal of epalrestate

Also Published As

Publication number Publication date
AU2009288037A1 (en) 2010-03-11
EP2326632A4 (en) 2012-05-30
CA2738231C (en) 2015-04-07
LT2326632T (lt) 2017-09-25
WO2010028132A3 (en) 2010-06-17
GB2476202A (en) 2011-06-15
US8906948B2 (en) 2014-12-09
WO2010028132A2 (en) 2010-03-11
DK2326632T3 (en) 2017-09-18
GB201105528D0 (en) 2011-05-18
EA023435B1 (ru) 2016-06-30
HUE034456T2 (en) 2018-02-28
EP2326632B8 (en) 2017-08-09
CA2738231A1 (en) 2010-03-11
CY1119752T1 (el) 2018-06-27
US9611234B2 (en) 2017-04-04
EP2326632A2 (en) 2011-06-01
CN102216281A (zh) 2011-10-12
SI2326632T1 (sl) 2017-11-30
US10464912B2 (en) 2019-11-05
EA201100245A1 (ru) 2011-08-30
PL2326632T3 (pl) 2017-10-31
EP2326632B1 (en) 2017-05-31
US20150057319A1 (en) 2015-02-26
US20110275682A1 (en) 2011-11-10
EA201200489A1 (ru) 2013-01-30
ES2639019T3 (es) 2017-10-25
US20170174643A1 (en) 2017-06-22
GB2476202B (en) 2012-04-11
CN102216281B (zh) 2014-11-05
AU2009288037B2 (en) 2014-08-14
PT2326632T (pt) 2017-09-05
EA016904B1 (ru) 2012-08-30

Similar Documents

Publication Publication Date Title
UA106209C2 (en) Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid
NZ599298A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2010011926A3 (en) A novel betaine cocrystal of epalrestat
WO2010127195A3 (en) Treatment of hemoglobin (hbf/hbg) related diseases inhibition of natural antisense transcript to hbf/hbg
WO2008108957A3 (en) Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
WO2008100867A3 (en) Novel inhibitors hepatitis c virus replication
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
MX340515B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
WO2009044392A3 (en) Novel sirna structures
WO2007075695A3 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2009140269A3 (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
WO2007095615A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatmentof pain
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
WO2010011922A3 (en) Novel crystalline salts of epalrestat
EP2106260A4 (en) INSULIN SENSITIZERS AND TREATMENT PROCEDURES THEREWITH
EP1857108A4 (en) PREVENTIVE OR THERAPEUTIC AGENT FOR HERPES VIRUS DISEASE